DRD5 and melanoma: Following mined data, all dopamine receptors were detected in melanomas; among them DRD1 in 33.8%, DRD2 in 11.3%, DRD3 in 4.5%, DRD4 in 62.4%, and DRD5 24.1% of samples (Figure 2).